Journal: Journal of Advanced Research

Article Title: Efficient improvement of the proliferation, differentiation, and anti-arthritic capacity of mesenchymal stem cells by simply culturing on the immobilized FGF2 derived peptide, 44-ERGVVSIKGV-53

doi: 10.1016/j.jare.2023.09.041

Figure Lengend Snippet: Antibody list.

Article Snippet: Membrane blocking was performed using 5 % skimmed milk in Tris-buffered saline for 1 h, followed by incubation with the appropriate primary antibodies against total ERK (Cat No. B7074, Assay Biotechnology, Fremont, CA, USA), phosphorylated ERK (Cat No. 9101 s, Cell Signaling Technology, Danvers, MA, USA), total AKT (Cat No. CSB-PA000855, CUSABIO, Houston, TX, USA), phosphorylated AKT (Cat No. CSB-PA008120, CUSABIO), IKKα (Cat No. 11930, Cell Signaling Technology), FGFR1 (Cat No. NBP2-33784, Novus Biologicals, Centennial, CO, USA), phosphorylated FGFR1 (Tyr653, Tyr654) (Cat No. 44-1140G, Invitrogen) polyclonal Antibody, FRS2 antibody (Cat No. 3836–100, BioVision, Waltham, MA, USA), phosphorylated FRS2-alpha (Cat No. 3864S, Cell Signaling) or ACTIN (Cat No. sc-8432, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4 °C.

Techniques: Staining, Plasmid Preparation

Journal: Oncology Letters

Article Title: Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway

doi: 10.3892/ol.2018.8986

Figure Lengend Snippet: Relative expression levels of BIRC5 mRNA and protein in different cell lines with or without SC79 treatment. (A) The effect of SC79 treatment on the expression levels of p-AKT in different cell lines. (B) Relative mRNA expression levels of BIRC5 in different cell lines. (C) Representative western blot analysis results of BIRC5. (D) Relative protein expression levels of BIRC5 in different cell lines. (E) The effect of SC79 treatment on the expression levels of VEGF in different cell lines. (F) The effect of SC79 treatment on the expression levels of BAI1 in different cell lines. (G) The effect of BAI1 treatment on the expression levels of MBD2 in different cell lines. *P<0.05 vs. untreated cells. BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; MBD2, methyl-CpG binding domain protein 2; BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; BAI1, brain-specific angiogenesis inhibitor 1; MBD2, methyl-CpG binding domain protein 2; p-Akt, phospho-Akt.

Article Snippet: The membranes were then incubated with corresponding primary antibodies including rabbit anti-BIRC5 polyclonal antibody (dilution, 1:1,000; catalog no. MBS151070; MyBioSource, Inc., San Diego, CA, USA), rabbit anti-VEGF polyclonal antibody (dilution, 1:1,000; catalog no. bs-0279R; Biomathematics and Statistics Scotland, Edinburgh, Scotland), rabbit anti-BAI1 polyclonal antibody (dilution, 1:1,000; catalog no. MBS8242484; MyBioSource, Inc.), rabbit anti-MBD2 polyclonal antibody (dilution, 1:1,000; catalog no. MBS126361; MyBioSource, Inc.), rabbit anti-phospho (p)-Akt polyclonal antibody (dilution, 1:1,000; catalog no. MBS330024; MyBioSource, Inc.) and rabbit anti-GAPDH polyclonal antibody (dilution, 1:1,000; catalog no. MBS9216842; MyBioSource, Inc.) overnight at 4°C.

Techniques: Expressing, Western Blot, Binding Assay